14d
YD Bio Limited Announces Major Milestones and Unveils Robust 2026 Clinical and Commercial Roadmap
YD BioMed expects to advance two lead ophthalmology programs utilizing its LSC Exosome platform, each supported by targeted regulatory and clinical milestones, which the timing of these milestones ...
Taipei, Taiwan, Jan. 05, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited ("YD Bio” or the "Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ...
Discover the top 3 manufacturing mistakes CDMOs make and how to prevent them when scaling for next-generation oncology.
Zacks Small Cap Research on MSN
YDES: YD Biopharma is an integrated biotechnology company that is poised to have a transformational year as it expands business operations
YDES YD Bio (NASDAQ:YDES) is an integrated biotechnology company that combines diagnostics, precision medicine, and regenerative ophthalmology under a single commercial and development strategy. The ...
It seemed like a very promising cancer immunotherapy lead. CHO Pharma, in Taiwan, had discovered that it was possible to target solid tumours with an antibody against a cell-surface glycolipid called ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback